TNF-alpha antagonist induced lupus on three different agents.

Area of Science:

• Immunology
• Rheumatology
• Gastroenterology

Background:

• Biologic agents targeting tumor necrosis factor alpha (TNF alpha) are crucial for managing inflammatory conditions like Crohn's disease.
• A rare syndrome, anti-TNF induced lupus (ATIL), can manifest with symptoms similar to idiopathic systemic lupus erythematosus (SLE).

Observation:

• Extra-intestinal manifestations in inflammatory bowel disease, such as arthritis, can complicate diagnosis.
• A 28-year-old female with Crohn's disease developed severe arthritis after treatment with infliximab, adalimumab, and certolizumab.

Findings:

• The patient's disabling arthritis was identified as a clinical manifestation of anti-TNF induced lupus (ATIL).
• This case underscores the challenge in differentiating drug-induced arthritis from underlying disease activity in patients receiving anti-TNF therapy.

Implications:

• Recognizing ATIL is critical for accurate diagnosis and appropriate management in patients with inflammatory diseases treated with TNF alpha antagonists.
• Further research may elucidate the mechanisms and diagnostic criteria for ATIL, improving patient outcomes.